Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27714825 | 0.87 | CYP19A1 (0.56) | ALDH1A1MAPTKMT2ANPSR1LMNA | |
| SCHEMBL4233807 | 0.87 | ALDH1A1 (0.53) | ALDH1A1MAPTKMT2ANPSR1LMNA | |
| SCHEMBL13215174 | 0.86 | ALDH1A1 (0.49) | ALDH1A1MAPTKMT2ANPSR1LMNA | |
| SCHEMBL27735670 | 0.86 | MAPT (0.51) | ALDH1A1MAPTKMT2ANPSR1LMNA | |
| SCHEMBL4238772 | 0.84 | MAPT (0.62) | ALDH1A1MAPTKMT2ANPSR1LMNA | |
| SCHEMBL30365378 | 0.84 | MAPT (0.62) | ALDH1A1MAPTKMT2ANPSR1LMNA | |
| SCHEMBL27456246 | 0.84 | MAPT (0.50) | ALDH1A1MAPTKMT2ANPSR1LMNA | |
| SCHEMBL6232066 | 0.84 | GPR35 (0.49) | ALDH1A1MAPTKMT2ALMNAGPR35 | |
| SCHEMBL9699858 | 0.83 | CYP19A1 (0.58) | ALDH1A1MAPTKMT2ANPSR1LMNA | |
| SCHEMBL27719953 | 0.83 | CYP19A1 (0.58) | ALDH1A1MAPTKMT2ANPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2021-07-01 | — | — | US | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10294218-B2 | 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity | VIROSTATICS SRL (IT) | 2019-05-21 | — | — | US | disclosed |
| EP-3442947-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme Inc (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| EP-2887943-B1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES | VIROSTATICS SRL (IT) | 2017-12-06 | — | — | EP | disclosed |
| EP-2887943-B1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES | VIROSTATICS SRL (IT) | 2017-12-06 | — | — | EP | disclosed |
| US-20140057911-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS | VIROSTATICS SRL (IT) | 2014-02-27 | — | — | US | disclosed |
| US-20140057911-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS | VIROSTATICS SRL (IT) | 2014-02-27 | — | — | US | disclosed |
| US-8318731-B2 | Pyrrolopyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20100204197-A1 | PYRROLOPYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
| EP-2185562-A1 | PYRROLOPYRIMIDINES | Janssen Pharmaceutica, N.V. (BE) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016132-A1 | PYRROLOPYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-05 | — | — | WO | disclosed |
| US-7250410-B2 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | VIA PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1392663-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098865-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294218-B2 | 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity | DUT, UMPS, DPYD | ALDH1A1 872/4885MAPT 1733/4885KMT2A 1615/4885 |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | ALDH1A1 185/4885MAPT 3035/4885KMT2A 17/4885 |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | ALDH1A1 185/4885MAPT 3035/4885KMT2A 17/4885 |
| US-20100204197-A1 | PYRROLOPYRIMIDINES | PLK4, PLK2, PLK3 | ALDH1A1 2934/4885MAPT 2102/4885KMT2A 3070/4885 |
| US-20140057911-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS | DPYD, ABL1, BRD4 | ALDH1A1 507/4885MAPT 2753/4885KMT2A 219/4885 |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | PDE7A, PDE3B, PDE3A | ALDH1A1 395/4885MAPT 4388/4885KMT2A 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.